drugset / Trial / NCT03397537
Neoadjuvant Endocrine Therapy in Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study aimed to compare the duration to complete or partial response (CR/PR) and the overall response rates (ORR) after six months of neoadjuvant endocrine therapy between pre-menopausal group and post-menopausal group with highly endocrine responsive operable mammary carcinoma.
Timeline
- Start
- 2012-09
- Primary completion
- 2017-07
- Completion
- 2017-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |
| Subject | Triptorelin | Other / unclassified | 3.75 mg | Intramuscular |